Deborah Levine, MD; Robert J. McDonald, MD, PhD; Herbert Y. Kressel, MD
JAMA. 2018;320(18):1853-1854. doi:10.1001/jama.2018.13362
This Viewpoint discusses the retention of gadolinium, used in contrast-enhanced MRI, in skin and kidney tissue and the efforts of experts from radiological societies, the NIH, and the FDA to study the safety of this element in clinical use.
John A. Harvin, MD, MS; Susan H. Wootton, MD; Charles C. Miller, PhD
JAMA. 2018;320(18):1855-1856. doi:10.1001/jama.2018.13607
This Viewpoint discusses the use of quality improvement reviews to build consensus about when randomized trials of competing treatment strategies are indicated and to inform the design and conduct of comparative effectiveness trials in emergency trauma.
Janet S. Wright, MD; Hilary K. Wall, MPH; Matthew D. Ritchey, PT, DPT, OCS, MPH
JAMA. 2018;320(18):1857-1858. doi:10.1001/jama.2018.13326
This Viewpoint describes the Million Hearts initiative, a US Centers for Disease Control and Prevention (CDC) and Centers for Medicare & Medicaid Services program aimed at preventing 1 million acute cardiovascular (CV) events by improving key cardiovascular disease (CVD) risk factors, and summarizes two 2018 CDC reports describing the burden of preventable CVD deaths and the slow rate of improving population-level measures of CV health.
William E. Bruhn; Elizabeth A. Fracica, MD, MPH; Martin A. Makary, MD, MPH
JAMA. 2018;320(18):1859-1860. doi:10.1001/jama.2018.13604
This Viewpoint explains how group purchasing organizations (GPOs) – companies that purchase devices, supplies, and medication from multiple manufacturers and serve as single supply sources for hospitals and medical centers – contribute to supply shortages, higher prices, and limited product selection, and proposes policy solutions to overcome the adverse effects of the arrangements.